MyAmyloidosisTeam

Are there clinical trials studying vutrisiran (Amvuttra) for polyneuropathy in wild-type ATTR amyloidosis?

Currently, vutrisiran (Amvuttra) is FDA-approved for hereditary ATTR (hATTR) amyloidosis with polyneuropathy, and more recently for ATTR cardiomyopathy (ATTR-CM). Its approval for wild-type ATTR polyneuropathy Show Full Answer

Are there clinical trials studying vutrisiran (Amvuttra) for polyneuropathy in wild-type ATTR amyloidosis?

Currently, vutrisiran (Amvuttra) is FDA-approved for hereditary ATTR (hATTR) amyloidosis with polyneuropathy, and more recently for ATTR cardiomyopathy (ATTR-CM). Its approval for wild-type ATTR polyneuropathy specifically is still being explored. Here's what is currently known about vutrisiran and wild-type ATTR:

- Vutrisiran is not yet approved for wild-type ATTR polyneuropathy
- It is one of several drugs being studied in clinical trials for wild-type ATTR amyloidosis
- Currently approved treatments for wild-type ATTR focus more on heart-related symptoms, using stabilizers like tafamidis and acoramidis

Since wild-type ATTR develops with age rather than genetics, gene-silencing drugs like vutrisiran target a different step in the process, which is why research is still ongoing.

Talking with an amyloidosis specialist about current or upcoming clinical trials would be the best way to explore whether this could be an option. Websites like ClinicalTrials.gov can also help find active studies.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

8 Amyloidosis Treatments and Their Side Effects

Life Expectancy With Amyloidosis: Prognosis for Different Types